| FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular … C Cremolini, F Loupakis, C Antoniotti, C Lupi, E Sensi, S Lonardi, S Mezi, ... The Lancet Oncology 16 (13), 1306-1315, 2015 | 1117 | 2015 |
| Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer F Loupakis, C Cremolini, G Masi, S Lonardi, V Zagonel, L Salvatore, ... New England Journal of Medicine 371 (17), 1609-1618, 2014 | 1102 | 2014 |
| Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis F Petrelli, G Tomasello, K Borgonovo, M Ghidini, L Turati, P Dallera, ... JAMA oncology 3 (2), 211-219, 2017 | 758 | 2017 |
| Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with … C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ... The Lancet Oncology 21 (4), 497-507, 2020 | 255 | 2020 |
| Association of obesity with survival outcomes in patients with cancer: a systematic review and meta-analysis F Petrelli, A Cortellini, A Indini, G Tomasello, M Ghidini, O Nigro, M Salati, ... JAMA Network Open 4 (3), e213520-e213520, 2021 | 249 | 2021 |
| Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis F Petrelli, D Signorelli, M Ghidini, A Ghidini, EG Pizzutilo, L Ruggieri, ... Cancers 12 (3), 546, 2020 | 216 | 2020 |
| Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results … C Cremolini, F Loupakis, C Antoniotti, S Lonardi, G Masi, L Salvatore, ... Annals of oncology 26 (6), 1188-1194, 2015 | 189 | 2015 |
| FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis G Tomasello, F Petrelli, M Ghidini, A Russo, R Passalacqua, S Barni JAMA oncology 3 (7), e170278-e170278, 2017 | 188 | 2017 |
| The Protein Imager: a full-featured online molecular viewer interface with server-side HQ-rendering capabilities G Tomasello, I Armenia, G Molla Bioinformatics 36 (9), 2909-2911, 2020 | 139 | 2020 |
| RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma S Qin, RS Finn, M Kudo, T Meyer, A Vogel, M Ducreux, TM Macarulla, ... Future Oncology 15 (16), 1811-1822, 2019 | 139 | 2019 |
| The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first … G Fucà, V Guarini, C Antoniotti, F Morano, R Moretto, S Corallo, ... British journal of cancer 123 (3), 403-409, 2020 | 138 | 2020 |
| Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: a meta-analysis of 17 published studies G Tomasello, F Petrelli, M Ghidini, E Pezzica, R Passalacqua, ... European Journal of Surgical Oncology 43 (9), 1607-1616, 2017 | 125 | 2017 |
| Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO E Dell’Aquila, C Cremolini, T Zeppola, S Lonardi, F Bergamo, G Masi, ... Annals of Oncology 29 (4), 924-930, 2018 | 121 | 2018 |
| The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: a systematic review and pooled analysis F Petrelli, M Ghidini, V Lonati, G Tomasello, K Borgonovo, M Ghilardi, ... European Journal of Cancer 84, 141-148, 2017 | 121 | 2017 |
| FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial … A Falcone, C Cremolini, G Masi, S Lonardi, V Zagonel, L Salvatore, ... Journal of Clinical Oncology 31 (15_suppl), 3505-3505, 2013 | 119 | 2013 |
| Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast … A Urruticoechea, M Rizwanullah, SA Im, ACS Ruiz, I Láng, G Tomasello, ... Journal of Clinical Oncology 35 (26), 3030-3038, 2017 | 117 | 2017 |
| Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO C Cremolini, C Antoniotti, S Lonardi, F Bergamo, E Cortesi, G Tomasello, ... Annals of oncology 29 (7), 1528-1534, 2018 | 109 | 2018 |
| Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer E Bajetta, I Floriani, M Di Bartolomeo, R Labianca, A Falcone, ... Annals of oncology 25 (7), 1373-1378, 2014 | 107 | 2014 |
| Comparative effectiveness of gemcitabine plus nab-paclitaxel and FOLFIRINOX in the first-line setting of metastatic pancreatic cancer: a systematic review and meta-analysis S Pusceddu, M Ghidini, M Torchio, F Corti, G Tomasello, M Niger, N Prinzi, ... Cancers 11 (4), 484, 2019 | 99 | 2019 |
| Maintenance therapy with panitumumab alone vs panitumumab plus fluorouracil-leucovorin in patients with RAS wild-type metastatic colorectal cancer: a phase 2 randomized … F Pietrantonio, F Morano, S Corallo, R Miceli, S Lonardi, A Raimondi, ... JAMA oncology 5 (9), 1268-1275, 2019 | 98 | 2019 |
